Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2026)

Prelude Therapeutics has disclosed EBITDA Margin across 3 years of filings, most recently posting 227.82% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 227.82%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 465.62% (changed N/A YoY), and the FY2025 annual result was 819.81%, up 99963.0% from the prior year.
• EBITDA Margin came in at 227.82% for Q1 2026 at Prelude Therapeutics, up from 291.68% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 227.82% in Q1 2026 to a low of 1060.47% in Q3 2024.
• The 3-year median for EBITDA Margin is 303.42% (2025), against an average of 520.99%.
• Peak annual rise in EBITDA Margin reached 75705 bps in 2025, while the deepest fall reached 42989 bps in 2025.
• Prelude Therapeutics' EBITDA Margin stood at 721.58% in 2024, then surged by 60 bps to 291.68% in 2025, then increased by 22 bps to 227.82% in 2026.
• The last three EBITDA Margin figures came in at 227.82% (Q1 2026), 291.68% (Q4 2025), and 303.42% (Q3 2025), per Business Quant data.